NeoGenomics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
NeoGenomics, Inc. (NEO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $12.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-02-17
- NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $12.80M, a 48.84% increase from fiscal 2024.
- NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $8.60M, a 38.71% increase from fiscal 2023.
- NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $6.20M, a 25.30% decline from fiscal 2022.
- NeoGenomics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $8.30M, a 29.06% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|
| 2025-12-31 | $12.80M 10-K · filed 2026-02-17 | |
| 2024-12-31 | $8.60M 10-K · filed 2026-02-17 | |
| 2023-12-31 | $6.20M 10-K · filed 2026-02-17 | |
| 2022-12-31 | $8.30M 10-K · filed 2025-02-18 | |
| 2021-12-31 | $11.70M 10-K · filed 2024-02-20 | |
| 2020-12-31 | $5.20M 10-K · filed 2023-02-24 | |
| 2019-12-31 | $5.50M 10-K · filed 2022-02-25 | |
| 2018-12-31 | $5.50M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $3.60M 10-K · filed 2020-02-28 | $3.62M 10-K · filed 2018-03-13 |
| 2016-12-31 | $2.20M 10-K · filed 2019-02-26 | $2.17M 10-K · filed 2017-03-14 |
| 2015-12-31 | $871.00K 10-K · filed 2018-03-13 | |
| 2014-12-31 | $540.00K 10-K · filed 2017-03-14 | |
| 2013-12-31 | $349.00K 10-K · filed 2016-04-18 | |
| 2012-12-31 | $218.00K 10-K · filed 2015-03-03 | |
| 2011-12-31 | $321.00K 10-K · filed 2014-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |